Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.
Saved in:
| Title: | Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. |
|---|---|
| Authors: | Kahn SE; Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle., Deanfield JE; Institute of Cardiovascular Science, University College London, London, U.K., Jeppesen OK; Novo Nordisk A/S, Søborg, Denmark., Emerson SS; Department of Biostatistics, University of Washington, Seattle, WA., Boesgaard TW; Novo Nordisk A/S, Søborg, Denmark., Colhoun HM; Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, U.K., Kushner RF; Department of Medicine, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL., Lingvay I; Department of Internal Medicine/Endocrinology and Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX., Burguera B; Endocrinology & Metabolism Institute, Cleveland Clinic, Cleveland, OH., Gajos G; Department of Coronary Artery Disease and Heart Failure, Jagiellonian University Medical College, Kraków, Poland., Horn DB; Department of Surgery, John P. and Katherine G. McGovern Medical School, University of Texas, Houston, TX., Hramiak IM; Western University, London, Ontario, Canada., Jastreboff AM; Endocrinology and Metabolism, Department of Medicine, and Pediatric Endocrinology, Department of Pediatrics, Yale School of Medicine, New Haven, CT., Kokkinos A; First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece., Maeng M; Department of Cardiology, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Matos ALSA; Novo Nordisk A/S, Søborg, Denmark., Tinahones FJ; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), CIBERobn, and Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Malaga University, Málaga, Spain., Lincoff AM; Department of Cardiovascular Medicine, Cleveland Clinic, and Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH., Ryan DH; Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle.; Pennington Biomedical Research Center, Baton Rouge, LA. |
| Corporate Authors: | SELECT Trial Investigators |
| Source: | Diabetes care [Diabetes Care] 2024 Aug 01; Vol. 47 (8), pp. 1350-1359. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Multicenter Study |
| Journal Info: | Publisher: American Diabetes Association Country of Publication: United States NLM ID: 7805975 Publication Model: Print Cited Medium: Internet ISSN: 1935-5548 (Electronic) Linking ISSN: 01495992 NLM ISO Abbreviation: Diabetes Care Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
